Cdk6 Antibody (F-7): sc-390493
- Cdk6 Antibody (F-7) is a mouse monoclonal IgG2b κ, cited in 7 publications, provided at 200 µg/ml
- raised against amino acids 230-326 mapping at the C-terminus of Cdk6 of human origin
- recommended for detection of Cdk6 of mouse, rat and human origin by WB, IP, IF and ELISA
- See Cdk6 (DCS-83): sc-53638 for Cdk6 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2b BP-HRP is the preferred secondary detection reagent for Cdk6 Antibody (F-7) for WB applications. This reagent is now offered in a bundle with Cdk6 Antibody (F-7) (see ordering information below).
Cdk6 Antibody (F-7) is a mouse monoclonal IgG2b antibody that detects Cdk6 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Cdk6 plays a crucial role in cell cycle regulation, particularly in the transition from the G1 phase to S phase, by forming complexes with cyclins D1, D2, and D3. This interaction is vital for the phosphorylation of target substrates that drive cell cycle progression, making anti-Cdk6 antibody (F-7) a key player in cellular proliferation and differentiation. Dysregulation of Cdk6 activity has been implicated in various cancers, highlighting its importance as a potential therapeutic target. Cdk6 (F-7) antibody provides a reliable tool for researchers studying the mechanisms of cell cycle control and the implications of Cdk6 in oncogenesis, enabling deeper insights into cancer biology and potential treatment strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Cdk6 Antibody (F-7) References:
- CDK6 binds and promotes the degradation of the EYA2 protein. | Kohrt, D., et al. 2014. Cell Cycle. 13: 62-71. PMID: 24196439
- Hedgehog signaling drives medulloblastoma growth via CDK6. | Raleigh, DR., et al. 2018. J Clin Invest. 128: 120-124. PMID: 29202464
- CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks. | Uras, IZ., et al. 2019. Blood. 133: 1677-1690. PMID: 30635286
- Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. | Martin, M., et al. 2020. Future Oncol. 16: 2763-2778. PMID: 32781837
- miR‑449a‑5p suppresses CDK6 expression to inhibit cardiomyocyte proliferation. | Li, B., et al. 2021. Mol Med Rep. 23: PMID: 33179102
- Activation of miR-500a-3p/CDK6 axis suppresses aerobic glycolysis and colorectal cancer progression. | Liu, Y., et al. 2022. J Transl Med. 20: 106. PMID: 35241106
- Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer. | Yang, S., et al. 2022. Front Genet. 13: 854211. PMID: 35571043
- CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer. | Chen, X., et al. 2022. Eur J Med Res. 27: 105. PMID: 35780240
- Targeting CDK6 in hormone receptor-positive breast cancer: inhibitor discovery for precision oncology through dynamics study. | Khatoon, Z., et al. 2023. J Biomol Struct Dyn. 1-13. PMID: 38127416
- YTHDC1 aggravates high glucose-induced retinal vascular endothelial cell injury via m6A modification of CDK6. | Zhou, Q., et al. 2024. Biol Direct. 19: 54. PMID: 38978074
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdk6 Antibody (F-7) | sc-390493 | 200 µg/ml | $322.00 | |||
Cdk6 Antibody (F-7): m-IgG2b BP-HRP Bundle | sc-548623 | 200 µg Ab; 10 µg BP | $361.00 |